Whereas systemic application of osteoprotegerin is known to decrease osteolysis and tumor growth [8], two similar experiments have shown that osteoprotegerin produced locally by metastatic cancer cells in the bone environment can lead to a decrease [9] or an increase [12] in osteolysis and tumor growth. Here, TNFRSF11B is linked to neoplasm.